Xuedan Du1, Jinting Wu2, Ye Zhao3, Bin Wang2, Xiaobo Ding2, Qiuyan Lin4, Yingyu Chen5, Jinduo Zhao3, Lixiao Liu3, Xiaolu Mao2, Zhen Fang2, Chunhong Zhang6, Wenfeng Li7. 1. Department of Oncology, Lishui Central Hospital, Lishui, Zhejiang, People's Republic of China. 2. Department of Oncology, The First Affiliated Hospital of Wenzhou Medical University, 2 Fuxue Road, Wenzhou, 325000, Zhejiang, People's Republic of China. 3. Department of Obstetrics and Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China. 4. Department of Oncology, Ruian City People's Hospital, Wenzhou, Zhejiang, People's Republic of China. 5. Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China. 6. Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China. 7. Department of Oncology, The First Affiliated Hospital of Wenzhou Medical University, 2 Fuxue Road, Wenzhou, 325000, Zhejiang, People's Republic of China. liwenfeng@wmu.edu.cn.
Abstract
METHODS: In this study, we developed a strategy for the prevention and therapy of melanoma using a whole-cell vaccine combined with a CpG/αOX40/cGAMP triple adjuvant. The CpG/αOX40/cGAMP triple adjuvant was used to co-culture melanoma cells in vitro to induce immunogenic death of tumor cells. The mixture of inactivated tumor cells and the triple drug was an optimized tumor whole-cell vaccine, which was injected subcutaneously into mice for tumor prevention and therapy. Furthermore, we analyzed the changes of immune cells in spleen and tumor by flow cytometry and immunohistochemistry, and detected the changes of cytokines after vaccine application by cytometric bead array to explore the specific mechanism of vaccine. RESULTS: In vaccine prevention and therapy experiments, it was observed that the tumor growth was significantly inhibited in the whole-cell vaccine group, and the survival time of mice was significantly prolonged. Flow cytometry results showed that the proportion of CD4+ T cells and CD8+ T cells in tumor of mice in vaccine group was higher than that in control group, especially the CD4+ T cells. CONCLUSION: The optimized vaccine has the unique ability to amplify tumor-specific CD4+ T cells, which improves antitumor sensitivity, and has a significant effect on the prevention and therapy of melanoma mice.
METHODS: In this study, we developed a strategy for the prevention and therapy of melanoma using a whole-cell vaccine combined with a CpG/αOX40/cGAMP triple adjuvant. The CpG/αOX40/cGAMP triple adjuvant was used to co-culture melanoma cells in vitro to induce immunogenic death of tumor cells. The mixture of inactivated tumor cells and the triple drug was an optimized tumor whole-cell vaccine, which was injected subcutaneously into mice for tumor prevention and therapy. Furthermore, we analyzed the changes of immune cells in spleen and tumor by flow cytometry and immunohistochemistry, and detected the changes of cytokines after vaccine application by cytometric bead array to explore the specific mechanism of vaccine. RESULTS: In vaccine prevention and therapy experiments, it was observed that the tumor growth was significantly inhibited in the whole-cell vaccine group, and the survival time of mice was significantly prolonged. Flow cytometry results showed that the proportion of CD4+ T cells and CD8+ T cells in tumor of mice in vaccine group was higher than that in control group, especially the CD4+ T cells. CONCLUSION: The optimized vaccine has the unique ability to amplify tumor-specific CD4+ T cells, which improves antitumor sensitivity, and has a significant effect on the prevention and therapy of melanoma mice.
Authors: Sara M Mangsbo; Linda C Sandin; Kerstin Anger; Alan J Korman; Angelica Loskog; Thomas H Tötterman Journal: J Immunother Date: 2010-04 Impact factor: 4.456
Authors: João Conniot; Anna Scomparin; Carina Peres; Eilam Yeini; Sabina Pozzi; Ana I Matos; Ron Kleiner; Liane I F Moura; Eva Zupančič; Ana S Viana; Hila Doron; Pedro M P Gois; Neta Erez; Steffen Jung; Ronit Satchi-Fainaro; Helena F Florindo Journal: Nat Nanotechnol Date: 2019-08-05 Impact factor: 39.213